Lilly received a $375 million order for GSK/Sanofi to provide 200 million doses of the new crown vaccine

At present, the world's major pharmaceutical companies are actively promoting coVID-19 treatment research and development.
two more drugs have recently received orders from government and public health agencies.
announced Wednesday that the U.S. government has struck a $375 million deal with the company to buy 300,000 doses of Lilly antibody therapy drug bamlanivimab (LY-CoV555).
that the deal was possible on the premise that LY-CoV555 would be authorized by the FDA for emergency use.
addition, the agreement provides that the U.S. government will be provided with the option to add another 650,000 doses and that patients will not be paid for the drug.
that although Lilly LY-CoV555 had previously suspended its research for lack of evidence of efficacy, that did not seem to stop the U.S. government from betting hugely on the drug.
reason for the suspension was that "in the hospital population, the clinical value of LY-CoV555 treatment interventions is very low."
" supervisory board, NIAID, noted that LY-CoV555 is unlikely to help hospitalized COVID-19 patients recover from the advanced stages of the disease.
: Lilly's third-quarter global revenue of $5,741 million and the suspension of new crown antibody trials for hospitalized patients, however, Lilly had previously applied to the FDA for an emergency use authorization for LY-CoV555 in early October.
said it remained confident that LY-CoV555 would prevent the development of the disease in early COVID-19 patients.
Based on previous trial data from Lilly and Incyte Corporation, LY-CoV555 combined with Gilead's Remxive reduces recovery time and improves clinical outcomes in patients with COVID-19 compared to the use of Redsheed alone.
The purchase agreement from the government is undoubtedly good news for LY-CoV555, but even if the LY-CoV555 is approved by the FDA, Lilly will lag behind Regeneration, which reached a $450 million supply agreement with the U.S. government in July.
has begun to increase production capacity, guaranteed to produce up to 300,000 doses of COVID-19 therapeutic drugs and 1.3 million doses of COVID-19 preventive drugs.
On the other hand, while Sanofi and GlaxoSmithKline are not the front-runners in the COVID-19 vaccine research and development competition, the two companies have said they will provide 200 million doses of the experimental new crown vaccine jointly developed by COVAX.
details of the agreement between the two companies and COVAX have not been released.
COVAX was co-sponsored and led by the Global Alliance for Vaccine Immunization (GAVI), the World Health Organization (WHO) and the Alliance for Innovation in Epidemiological Prevention (CEPI), with the aim of accelerating the development and production of new coronary pneumonia vaccines and ensuring equitable access to vaccines in all countries, including access to safe and effective vaccines to non-vaccine research and development capacity or low-income countries.
Although Sanofi and GlaxoSmithKline's COVID-19 vaccines have not reached the late stages of trial, experts say the two pharmaceutical giants' reliable professional platforms and global supply capabilities are expected to be key players in the COVID-19 vaccination program in the long term.
, the two companies are expected to begin late-stage trials of the COVID-19 vaccine by the end of the year.
if the clinical trial is successful, the two companies plan to submit the procedure for approval in the first half of next year.
, the two companies are expanding production to reach the capacity to produce up to 1 billion doses a year.
addition to the agreement with COVAX, the two companies are working with the European Union to provide 300 million doses of the vaccine and up to 600 million doses to the U.S. market.
, Pfizer, Johnson and Johnson, AstraZeneta, Moderna and Novavax are conducting late-stage trials of their vaccine products.
the faster pace is the new mRNA vaccine developed by Pfizer and Moderna, which experts say could be available as soon as late 2020 or early 2021.